BusinessLogrBusinessLogr
  • Home
  • Stocks
  • Finance
  • Business
  • Company
  • Economy
  • Industry
  • Investing
  • Car News
  • Contact Us!
Reading: Biocon shares get a leg up from hepatitis-C drug launch
Share
Aa
BusinessLogrBusinessLogr
Aa
  • Home
  • Stocks
  • Finance
  • Business
  • Company
  • Economy
  • Industry
  • Investing
  • Car News
  • Contact Us!
Follow US
© 2023 BusinessLogr News Network.
BusinessLogr > Industry > Biocon shares get a leg up from hepatitis-C drug launch
Industry

Biocon shares get a leg up from hepatitis-C drug launch

deep
Last updated: 2015/12/29 at 6:06 AM
deep Published December 29, 2015
Share
3 Min Read
SHARE

Biocon has said it will also launch the drug at a fraction of the international price. Photo: Hemant Mishra/Mint

Biocon’s shares rose 5.36% on BSE on Thursday, a move attributed to the company’s announcement that it is launching Cimivir-L, a drug to treat hepatitis-C. The drug is for the treatment of hepatitis-C genotype 1 patients who represent one-fourth of 18 million such patients in India, according to a company statement.

Biocon and a clutch of other Indian pharmaceutical companies have been licensed by the drug’s innovator, Gilead Sciences Inc., to sell a few of its hepatitis-C drugs in India. On 15 December, Natco Pharma Ltd announced the launch of the same drug, a version of Gilead’s Harvoni. Natco’s shares did not react the way Biocon’s did, although the former’s shares have gained 4.7% till date.

Click here for enlarge

The Indian companies plan to sell these medicines at lower prices than the innovator and cover a larger patient base. Natco Pharma, for instance, said it will sell its version of Harvoni at Rs.5,000 for a bottle of 28 tablets. For a 12-week dose, it works out to Rs.15,000. Gilead’s website mentions that it has priced Harvoni for developing countries at $400 a bottle, or Rs.26,500 at current exchange rates. Biocon has said it will also launch the drug at a fraction of the international price.

India’s position as a country with one of the largest number of hepatitis-C patients makes it an attractive market. How much of this target segment actually gets on to these new drugs is what will determine the extent to which the Indian permit holders benefit. Also, competition among them to grab a bigger slice of this market is another risk to watch out for.

One development that continues to benefit Biocon is the listing of Syngene International Ltd, which netted it Rs.550 crore in funds. Also, the share has gained 58% from its issue price. Since Biocon continues to own a majority stake, it benefits as well. Biocon’s September quarter did see somewhat slower sales growth, partly due to capacity constraints and due to its focus on shifting to more profitable products.

The December quarter should provide an update on how these factors are playing out. The performance of its existing business and that of Syngene should drive stock performance in the near to medium term, while its research programmes are likely to play a bigger role in the longer run.
[“source -livemint”]

You Might Also Like

Why a cutting-edge billing system is essential in 2025: Accelerate Your Telecom Growth

SEO for Life Sciences: How to Outrank Competitors and Drive Organic Traffic

Cognitive Market Research: A Method for Obtaining Industry-Specific Impactful Insights via Industry Blogs

How to Start a Blog That Makes You Money

Simulated intelligence Patterns in Telecom 2025: Tackling Basic Industry Difficulties

TAGGED: Biocon shares get a leg up from hepatitis-C drug launch
deep December 29, 2015
Share this Article
Facebook Twitter Email Print
Share
Previous Article Voltas’s prospects factored into rich valuations as stock runs up
Next Article Rail freight volume tumbles in November

Most Viewed Posts

  • Environmental thematic investing set for strong growth in 2022
  • Second income center in banks
  • T-Mobile Adds Mexico, Canada to Simple Choice Plan
  • Tieghan gerard income in banks
  • 20 Fitness Franchises: Planet Fitness and Beyond

Most Viewed Posts

  • Environmental thematic investing set for strong growth in 2022
  • Second income center in banks
  • T-Mobile Adds Mexico, Canada to Simple Choice Plan
  • Tieghan gerard income in banks
  • 20 Fitness Franchises: Planet Fitness and Beyond

Recent Posts

  • How to Start and Set Up Your Company Blog for Success
  • 14 Magnificent Blogs From Large Businesses to Inspire Your Content Marketing

© 2023 BusinessLogr News Network.

Removed from reading list

Undo
Welcome Back!

Sign in to your account

Lost your password?